Focus Partners Wealth’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Focus Partners Wealth’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,214	Closed	-$424K	–	2149
2025 Q1	$424K	Sell	3,214 -293	-8%	-$36.5K	﹤0.01%	1416
2024 Q4	$293K	Sell	3,507 -56	-2%	-$4.6K	﹤0.01%	1564
2024 Q3	$261K	Buy	+3,563	New	+$268K	﹤0.01%	1375

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Focus Partners Wealth's ITCI Position: Q2 2025 in Review

Focus Partners Wealth sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,214 shares — an estimated $424K sold.

Focus Partners Wealth first reported a position in ITCI in Q3 2024 and held it in 3 quarters. The position peaked at $424K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Focus Partners Wealth reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Focus Partners Wealth sold 3,214 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $424K.
Focus Partners Wealth first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 3 quarters.
Focus Partners Wealth's Intra-Cellular Therapies Inc. position peaked at $424K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Focus Partners Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.